Article info
PDFResearch ethics
Stopping trials early for commercial reasons: the risk–benefit relationship as a moral compass
- Correspondence to: A S Iltis Center for Health Care Ethics, Saint Louis University, 221 N. Grand Blvd, Saint Louis, MO 63103, USA; iltisasslu.edu
Citation
Stopping trials early for commercial reasons: the risk–benefit relationship as a moral compass
Publication history
- Received March 12, 2004
- Accepted June 18, 2004
- Revised June 22, 2004
- First published June 30, 2005.
Online issue publication
June 30, 2005
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by the Journal of Medical Ethics
Other content recommended for you
- Clinical Research From Proposal to Implementation
- Internet-based crowdsourcing and research ethics: the case for IRB review
- Institutionally chartered Data and Safety Monitoring Boards: structured approaches to assuring participant safety in clinical research
- Manual ventilation to prevent hypoxaemia during endotracheal intubation of critically ill adults: protocol and statistical analysis plan for a multicentre randomised trial
- A public health perspective on research ethics
- A comparison of journal instructions regarding institutional review board approval and conflict-of-interest disclosure between 1995 and 2005
- DNA Methylation Analysis to predict Regression of high-grade anal Intraepithelial Neoplasia in HIV+ men (MARINE): a cohort study protocol
- Variations in institutional review board processes and consent requirements for trauma research: an EAST multicenter survey
- The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: protocol for an international multicentre randomised controlled trial
- Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol